Proceedings from Part 2 of a 2-part satellite symposia series during the 2013 Gastrointestinal Cancers Symposium. Including perspectives from Charles S Fuchs, Philip A Philip, Alan P Venook, Andrew X Zhu and Matthew Kulke. (Video Program)
TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.
OVERVIEW OF ACTIVITY
Given the prevalent nature of the disease, extensive resources are allocated to colorectal cancer (CRC) research and education. Of interest, however, although individually less frequently encountered, the collection of other “non-CRC” gastrointestinal (GI) cancers accounts for more per annum cancer-related deaths than those attributed to tumors of the colon and rectum combined. In addition to maintaining a sound understanding of the conventional but distinct treatment algorithms applicable to each subtype of non-CRC GI cancer, practicing oncologists must now rationally integrate targeted agents into their individualized therapeutic recommendations for the safe and effective clinical management of diseases they seldom encounter.
These proceedings from a CME symposium held during the 2013 Gastrointestinal Cancers Symposium use the perspectives of renowned GI cancers experts to explore the self-described practice patterns of 25 clinical investigators and the supporting research database in a number of commonly encountered clinical situations. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers with the formulation of up-to-date clinical management strategies for various non-CRC GI cancers.
LEARNING OBJECTIVES
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. The participant should watch the video.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
Charles S Fuchs, MD, MPH
Director, Center for Gastrointestinal Cancer
Dana-Farber/Harvard Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Advisory Committee: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Genomic Health Inc, Pfizer Inc, Sanofi.
Philip A Philip, MD, PhD, FRCP
Professor of Oncology and Medicine
Director of GI and Neuroendocrine Tumors
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan
Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi; Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Onyx Pharmaceuticals Inc; Speakers Bureau: Amgen Inc, Bayer HealthCare Pharmaceuticals, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi.
Alan P Venook, MD
Professor of Clinical Medicine
University of California, San Francisco
San Francisco, California
Consulting Agreement: Sanofi; Contracted Research: Bayer HealthCare Pharmaceuticals, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Onyx Pharmaceuticals Inc.
Andrew X Zhu, MD, PhD
Director, Liver Cancer Research
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Advisory Committee: Abbott Laboratories, Bristol-Myers Squibb Company, Eisai Inc, Sanofi.
Matthew Kulke, MD, MMSc
Director, Program in Neuroendocrine and Carcinoid Tumors
Dana-Farber/Brigham and Women’s Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Consulting Agreements: Novartis Pharmaceuticals Corporation, Pfizer Inc.
MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Onyx Pharmaceuticals Inc, Regeneron Pharmaceuticals and Sanofi.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
A high-speed Internet connection
Introduction: Dr Love | |
Module 1: Dr Fuchs – Gastric Cancer |
|
Module 2: Dr Philip – Pancreatic Cancer |
|
Module 3: Dr Venook – Gastrointestinal Stromal Tumors |
|
Module 4: Dr Zhu – Hepatocellular Carcinoma |
|
Module 5: Dr Kulke – GI Neuroendocrine Tumors |
Watch video
(WiFi is recommended for best performance):